Related Experiment Video

Updated: Mar 7, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

12.1K

Rituximab in Neuromyelitis Optica Spectrum Disorders-Reply: Why Not as First-Line Therapy

Valentina Damato1, Amelia Evoli1, Raffaele Iorio2

  • 1Institute of Neurology, Fondazione Policlinico Universitario "A. Gemelli," Catholic University, Rome, Italy.

JAMA Neurology
|February 7, 2017
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

2.4K
Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay
05:45

Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay

Published on: April 5, 2019

24.3K

Related Experiment Videos

Last Updated: Mar 7, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

12.1K
Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

2.4K
Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay
05:45

Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay

Published on: April 5, 2019

24.3K

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K

Articles linked to this work by shared authors, journal, and citation graph.

New percentiles of gamma-glutamyl transferase serum levels in infants and the role of breastfeeding.

BMC pediatrics·2026

The Italian biliary atresia registry: Insights and lessons from the retrospective analysis of a 10-year period cohort.

Journal of pediatric gastroenterology and nutrition·2026

Cenobamate use in super-refractory status epilepticus: A report of three cases.

Epileptic disorders : international epilepsy journal with videotape·2026

Hepatitis A resurgence: time to reconsider routine pediatric immunization.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026

Relative frequencies of muscle specific kinase antibody myasthenia in 46 centres worldwide.

Brain : a journal of neurology·2026

Myasthenia gravis misdiagnosis in the era of innovative therapies: Uncovering pitfalls and patterns.

Journal of neuroimmunology·2026

Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial.

JAMA neurology·2026

Plasma Biomarkers for Neocortical Tau Burden.

JAMA neurology·2026

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

JAMA neurology·2026

Automated Speech Analysis to Identify Clinical, Anatomical, and Pathological Variants of Primary Progressive Aphasia.

JAMA neurology·2026

Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial.

JAMA neurology·2026

Road Traffic Noise, Noise Difference Between Residential Facades, and Risk of Parkinson Disease.

JAMA neurology·2026

Neuroprotection of engineered Clostridium butyricum-pMTL007-GLP-1 in A53T α-synuclein (α-syn) mouse model via PI3K/AKT/GSK-3β.

Journal of Zhejiang University. Science. B·2026

Incidence and clinical characteristics of amyotrophic lateral sclerosis during the post-COVID-19 Period: a population-based study from Isfahan, Iran.

Neurodegenerative disease management·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us